I think when the results of the completed BARDA trial are analysed and reported then it will have significant benefits for reimbursement in the US and improve awareness, confidence and marketshare. IMO the US military who I believe already use it through VA hospitals will likely consider it's wider appeal as reports are published of reatment in war zone victims.
Something to look forward to in supporting and driving growth.
Ann: AGM - Chairman and CEO address to shareholders, page-51
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.020(0.78%) |
Mkt cap ! $1.780B | |||
| Open | High | Low | Value | Volume |
| $2.61 | $2.63 | $2.56 | $2.465M | 952.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10700 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 24502 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |